FHTX Stock Forecast: Foghorn Therapeutics, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $5 — +180.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FHTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +180.9% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 2 Oct 2026 | Guggenheim | Maintains | Buy | $12 → $5.00 |
| 2 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $13 → $5.00 |
| 2 Oct 2026 | TD Cowen | Downgrade | Hold | — |
| 2 Oct 2026 | Wedbush | Downgrade | Neutral | $10 → $2.00 |
| 12 Mar 2026 | Wedbush | Reiterates | Outperform | $10 |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 18 Dec 2025 | BTIG | Initiates | Buy | — |
| 4 Dec 2025 | Stifel | Initiates | Buy | — |
| 7 Nov 2025 | Guggenheim | Initiates | Buy | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Apr 2025 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | B. Riley Securities | Initiates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2024 | Jefferies | Maintains | Buy | — |
| 24 Sept 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FHTX.
This page is one stock. Monday covers all of them.
FHTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FHTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Foghorn Therapeutics, Inc. returned −63.4% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FHTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 19.4×
- Price / sales
- 0.9×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 47% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 8.0%
- Net margin
- —
Higher than 60% of US stocks
- Return on equity
- —
- Return on assets
- 2.8%
- Dividend yield
- —
Higher than 63% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Foghorn Therapeutics, Inc. has a market value of $109.7M.
Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.
Net income over the same four quarters: −$64.6M, a −175.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$84.3M.
Trailing P/E: 19.4×.
Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.
Data provided by Twelve Data
FHTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FHTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FHTX
What is the FHTX stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FHTX stock a buy right now?
Of the 10 analysts covering Foghorn Therapeutics, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 56 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FHTX?
As at 18 Nov 2026, Foghorn Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will FHTX stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +180.9% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 56 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FHTX stock forecast for 2030?
No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
How has FHTX stock performed over the past year?
Foghorn Therapeutics, Inc. returned -63.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Foghorn Therapeutics, Inc. do?
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells.
About Foghorn Therapeutics, Inc.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.
CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com